Low Dose Aspirin and Omega 3 Fatty Acids in the Pro Resolving Pathway of Cardiovascular Disorders
Newer mechanisms of action of Acetyl Salicylic acid have been discovered in proresolving pathway of various disorders. Omega 3 fatty acids are also involved in the synthesis of resolvins via an aspirin triggered pathway. The present review aims to discuss the role of recently discovered aspirin triggered lipoxins, resolvins, protectins, maresins in understanding the pathophysiology of endothelial dysfunction in various cardiovascular disorders, especially hypertension. The concept of aspirin triggered lipoxins (15-epi-LXA4 and 15-epi-LX4)counteracting the action of LTB4.PGE2, and TXA2 is discussed. Aspirin triggered lipoxins also block the expression of IL-8 gene. Aspirin is the only known NSAID to induce NO in a dose dependent manner. In this chapter, we describe role of acetyl salicylic acid in the pro-resolution pathways that might prevent or reduce complications in patients with high blood pressure. Aspirin is a low cost intervention that can prevent the atherosclerosis of vessels by its anti-inflammatory, antiplatelet and proresolving abilities. Recent understanding of the pathophysiology of hypertension and proresolving pathways can help to understand the rational use of aspirin in prevention and reducing the complications of high blood pressure. A combination of aspirin and omega 3 fatty acids has potential benefits. DHA metabolites have been found to have potent role in the resolution pathway of inflammation. Future endeavors would focus on the identification of subset of high-risk hypertensive patients who will benefit most from aspirin, omega 3 fatty acids and DHA. Different dosage and time of initiation in various high-risk groups needs to be identified. Further research is also required to identify the correct time and the oral doses that will help in minimizing the long-term risk of future cardiovascular diseases.
Read full article: http://bp.bookpi.org/index.php/bpi/catalog/view/42/179/324-1